It’s no secret that the two existing PCSK9 cardiovascular drugs on the market, Amgen’s Repatha and Regeneron and Sanofi’s Praluent, are suffering from painfully slow launches. And on top of that, they could soon face a serious threat, thanks to a positive phase 3 readout from a more convenient option, one analyst argues.
